Matched comparison of decellularized homografts and bovine jugular vein conduits for pulmonary valve replacement in congenital heart disease.
Allografts
Decellularization
Heart valve disease
Tissue engineering
Journal
Cell and tissue banking
ISSN: 1573-6814
Titre abrégé: Cell Tissue Bank
Pays: Netherlands
ID NLM: 100965121
Informations de publication
Date de publication:
14 Mar 2023
14 Mar 2023
Historique:
received:
13
10
2022
accepted:
23
02
2023
entrez:
14
3
2023
pubmed:
15
3
2023
medline:
15
3
2023
Statut:
aheadofprint
Résumé
For decades, bovine jugular vein conduits (BJV) and classic cryopreserved homografts have been the two most widely used options for pulmonary valve replacement (PVR) in congenital heart disease. More recently, decellularized pulmonary homografts (DPH) have provided an alternative avenue for PVR. Matched comparison of patients who received DPH for PVR with patients who received bovine jugular vein conduits (BJV) considering patient age group, type of heart defect, and previous procedures. 319 DPH patients were matched to 319 BJV patients; the mean age of BJV patients was 15.3 (SD 9.5) years versus 19.1 (12.4) years in DPH patients (p = 0.001). The mean conduit diameter was 24.5 (3.5) mm for DPH and 20.3 (2.5) mm for BJV (p < 0.001). There was no difference in survival rates between the two groups after 10 years (97.0 vs. 98.1%, p = 0.45). The rate of freedom from endocarditis was significantly lower for BJV patients (87.1 vs. 96.5%, p = 0.006). Freedom from explantation was significantly lower for BJV at 10 years (81.7 vs. 95.5%, p = 0.001) as well as freedom from any significant degeneration at 10 years (39.6 vs. 65.4%, p < 0.001). 140 Patients, matched for age, heart defect type, prior procedures, and conduit sizes of 20-22 mm (± 2 mm), were compared separately; mean age BJV 8.7 (4.9) and DPH 9.5 (7.3) years (p = n.s.). DPH showed 20% higher freedom from explantation and degeneration in this subgroup (p = 0.232). Decellularized pulmonary homografts exhibit superior 10-year results to bovine jugular vein conduits in PVR.
Identifiants
pubmed: 36917328
doi: 10.1007/s10561-023-10082-4
pii: 10.1007/s10561-023-10082-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Commission
ID : No. 278453
Informations de copyright
© 2023. The Author(s).
Références
Abdelghani M, Nassif M, Blom NA, Van Mourik MS, Straver B, Koolbergen DR et al (2018) Infective endocarditis after melody valve implantation in the pulmonary position: a systematic review. J Am Heart Assoc 7:e008163
doi: 10.1161/JAHA.117.008163
pubmed: 29934419
pmcid: 6064882
Bobylev D, Horke A, Boethig D, Hazekamp M, Meyns B, Rega F et al (2022) 5-Year results from the prospective European multi-centre study on decellularized homografts for pulmonary valve replacement ESPOIR Trial and ESPOIR Registry data. Eur J Cardiothorac Surg 62(5):ezac219
doi: 10.1093/ejcts/ezac219
pubmed: 35425983
pmcid: 9615428
Boethig D, Westhoff-Bleck M, Hecker H, Ono M, Goerler A, Sarikouch S et al (2009) Bovine jugular veins in the pulmonary position in adults – 5 years’ experience with 64 implantations. Thorac Cardiovasc Surg 57:196–201
doi: 10.1055/s-0029-1185394
pubmed: 19670110
Boethig D, Schreiber C, Hazekamp M, Blanz U, Pretre R, Asfour B et al (2012) Risk factors for distal Contegra stenosis: results of a prospective European multicentre study. Thorac Cardiovasc Surg 60:195–204
doi: 10.1055/s-0031-1298062
pubmed: 22228091
Bokma JP, Winter MM, Oosterhof T, Vliegen HW, van Dijk AP, Hazekamp MG et al (2015) Individualised prediction of pulmonary homograft durability in tetralogy of Fallot. Heart 101:1717–1723
doi: 10.1136/heartjnl-2015-307754
pubmed: 26175476
Breymann T, Blanz U, Wojtalik MA, Daenen W, Hetzer R, Sarris G et al (2009) European Contegra multicentre study: 7-year results after 165 valved bovine jugular vein graft implantations. Thorac Cardiovasc Surg 57:257–269
doi: 10.1055/s-0029-1185513
pubmed: 19629887
Contegra pulmonary valved conduit FDA executive summary. 2020 FDA Pediatric advisory committee meeting. Last accessed 05.07.2022
Ebken JMN, Smart I, Ramm R, Goecke T, Jashari R, Böthig D, Horke A, Cebotari S, Tudorache I, Avsar M, Bobylev D, Haverich A, Sarikouch S, Hilfiker A (2021) Residual immune response towards decellularized homografts may be highly individual. Eur J Cardiothorac Surg 59(4):773–782
doi: 10.1093/ejcts/ezaa393
pubmed: 33544830
Fiore AC, Ruzmetov M, Huynh D, Hanley S, Rodefeld MD, Turrentine MW et al (2010) Comparison of bovine jugular vein with pulmonary homograft conduits in children less than 2 years of age. Eur J Cardio-Thorac 38:318–325
doi: 10.1016/j.ejcts.2010.01.063
Horke A, Bobylev D, Avsar M, Meyns B, Rega F, Hazekamp M et al (2020) Paediatric aortic valve replacement using decellularized allografts. Eur J Cardiothorac Surg 58(4):817–824
doi: 10.1093/ejcts/ezaa119
pubmed: 32443152
pmcid: 7890932
Jashari R (2021) Transplantation of cryopreserved human heart valves in Europe: 30 years of banking in Brussels and future perspectives. Cell Tissue Bank 22(4):519–537
doi: 10.1007/s10561-021-09902-2
pubmed: 33532987
pmcid: 7853167
Khanna AD, Hill KD, Pasquali SK, Wallace AS, Masoudi FA, Jacobs ML et al (2015) Benchmark outcomes for pulmonary valve replacement using the society of thoracic surgeons databases. Ann Thorac Surg 100:138–145
doi: 10.1016/j.athoracsur.2015.03.025
pubmed: 26007205
Marathe SP, Hussein N, Wallace FRO, Bell D, Yong M, Betts KS et al (2021) Comparison of homografts and bovine jugular vein conduits in the pulmonary position in patients <20 years of age. J Thorac Cardiovasc Surg 164:752–762
doi: 10.1016/j.jtcvs.2021.11.087
pubmed: 35058063
Meijer FMM, Kies P, Jongbloed MRM, Hazekamp MG, Koolbergen DR, Blom NA et al (2019) Excellent durability of homografts in pulmonary position analysed in a predefined adult group with tetralogy of Fallot. Interact Cardiovasc Thorac Surg 28:279–283
doi: 10.1093/icvts/ivy242
pubmed: 30102354
Patel PM, Herrmann JL, Rodefeld MD, Turrentine MW, Brown JW (2020) Bovine jugular vein conduit versus pulmonary homograft in the ross operation. Cardiol Young 30:323–327
doi: 10.1017/S1047951119003007
pubmed: 31847922
Poinot N, Fils JF, Demanet H, Dessy H, Biarent D, Wauthy P (2018) Pulmonary valve replacement after right ventricular outflow tract reconstruction with homograft vs Contegra(R): a case control comparison of mortality and morbidity. J Cardiothorac Surg 13:8
doi: 10.1186/s13019-018-0698-5
pubmed: 29343297
pmcid: 5773189
Ramm R, Goecke T, Köhler P, Tudorache I, Cebotari S, Ciubotaru A, Sarikouch S, Höffler K, Bothe F, Petersen B, Haverich A, Niemann H, Hilfiker A (2021) Immunological and functional features of decellularized xenogenic heart valves after transplantation into GGTA1-KO pigs. Regen Biomat 8:036
doi: 10.1093/rb/rbab036
Sandica E, Boethig D, Blanz U, Goerg R, Haas NA, Laser KT et al (2016) bovine jugular veins versus homografts in the pulmonary position: an analysis across two centers and 711 patients-conventional comparisons and time status graphs as a new approach. Thorac Cardiovasc Surg 64:25–35
pubmed: 26322831
Simon P, Kasimir MT, Seebacher G, Weigel G, Ullrich R, Salzer-Muhar U et al (2003) Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg 23:1002–1006
doi: 10.1016/S1010-7940(03)00094-0
pubmed: 12829079
Stammnitz C, Huscher D, Bauer UMM, Urban A, Nordmeyer J, Schubert S et al (2022) Nationwide registry-based analysis of infective endocarditis risk after pulmonary valve replacement. J Am Heart Assoc 11:e022231
doi: 10.1161/JAHA.121.022231
pubmed: 35179045
pmcid: 9075093
Waqanivavalagi S, Bhat S, Ground MB, Milsom PF, Cornish J (2020) Clinical performance of decellularized heart valves versus standard tissue conduits: a systematic review and meta-analysis. J Cardiothorac Surg 15:260
doi: 10.1186/s13019-020-01292-y
pubmed: 32948234
pmcid: 7501674
Williams DF, Bezuidenhout D, de Villiers J, Human P, Zilla P (2021) Long-term stability and biocompatibility of pericardial bioprosthetic heart valves. Front Cardiovasc Med 8:728577
doi: 10.3389/fcvm.2021.728577
pubmed: 34589529
pmcid: 8473620
Yong MS, Yim D, d’Udekem Y, Brizard CP, Robertson T, Galati JC et al (2015) Medium-term outcomes of bovine jugular vein graft and homograft conduits in children. ANZ J Surg 85:381–385
doi: 10.1111/ans.13018
pubmed: 25708132